K. Price

发表

Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV.

R. Gelber, A. Goldhirsch, J. Collins, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tamoxifen for early breast cancer: an overview of the randomised trials

Mike Clarke, Luc Bijnens, Michael Gnant, 1998, The Lancet.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX.

R. Gelber, A. Goldhirsch, F. Cardoso, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.

M. Bonetti, R. Gelber, A. Goldhirsch, 2002, Journal of the National Cancer Institute.

Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.

A. Giobbie-Hurder, E. Winer, R. Gelber, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Present and future projects of the international breast cancer study group

J. Forbes, F. Cavalli, R. Gelber, 1994, Cancer.

Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials.

R. Gelber, A. Goldhirsch, G. Viale, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

Patrick Neven, István Láng, A. Giobbie-Hurder, 2011, The Lancet. Oncology.

Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.

M. Climent, M. Regan, P. Francis, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Terry L. Smith, R. Collins, L. Holmberg, 1998, Lancet.

Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.

R. Gelber, A. Goldhirsch, M. Regan, 2013, Breast.

Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.

R. Gelber, L. Mazzucchelli, B. Gusterson, 2006, Journal of the National Cancer Institute.

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

B. Gusterson, A. Goldhirsch, R. Anbazhagan, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1–98 trial

P. Neven, H. Ditzel, B. Leyland-Jones, 2015, Breast Cancer Research and Treatment.

ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer

P. Neven, R. Gelber, B. Leyland-Jones, 2015, Breast Cancer Research and Treatment.

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.

P. Neven, R. Gelber, H. Ditzel, 2012, Journal of the National Cancer Institute.

Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer

A. Giobbie-Hurder, R. Gelber, K. Price, 2009, Clinical trials.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Ivanov, Harris, R. Collins, 2005, The Lancet.

Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial.

R. Gelber, A. Goldhirsch, M. Regan, 2013, Breast.

Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer.

R. Gelber, B. Gusterson, A. Goldhirsch, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant!© Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer

R. Gelber, R. Paridaens, A. Goldhirsch, 2010, Breast Cancer Research and Treatment.

Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil

R. Gelber, A. Coates, K. Price, 1999, The Lancet.

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

A. Giobbie-Hurder, E. Winer, E. Perez, 2014, The New England journal of medicine.

Adjuvant ovarian suppression in premenopausal breast cancer.

A. Giobbie-Hurder, E. Winer, R. Gelber, 2015, The New England journal of medicine.

Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer

J. Forbes, R. Gelber, A. Goldhirsch, 2007, British Journal of Cancer.

The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause

A. Goldhirsch, M. Regan, A. Coates, 2011, Breast Cancer Research and Treatment.

Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer

A. Giobbie-Hurder, R. Gelber, M. Regan, 2011, Breast Cancer Research.

BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer.

A. Giobbie-Hurder, J. Forbes, R. Gelber, 2009 .

Axillary node micrometastases and breast cancer

R. Gelber, A. Goldhirsch, K. Price, 1991, The Lancet.

Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93.

J. Forbes, R. Gelber, A. Goldhirsch, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract S1-8: Outcome According to CYP2D6 Genotype among Postmenopausal Women with Endocrine-Responsive Early Invasive Breast Cancer Randomized in the BIG 1-98 Trial

B. Leyland-Jones, G. Viale, B. Thürlimann, 2010 .

Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial

R. Gelber, C. Geyer, N. Wolmark, 2017, Annals of Surgical Oncology.

Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index

R. Gelber, A. Goldhirsch, A. Coates, 2005, The Lancet.

Routine tests during follow-up of patients after primary treatment for operable breast cancer. International (Ludwig) Breast Cancer Study Group (IBCSG)

R. Gelber, A. Goldhirsch, M. Castiglione, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer

R. Gelber, A. Goldhirsch, F. Cardoso, 2012, British Journal of Cancer.

Decreased immunoreactivity for p27 protein in patients with early‐stage breast carcinoma is correlated with HER‐2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status

R. Gelber, B. Gusterson, A. Goldhirsch, 2003, Cancer.

Early studies establishing the predictive and prognostic value of steroid hormone receptors measured levels of ER and PgR in Background: Tumor levels of steroid hormone receptors, a factor used to select adjuvant treatment for early-stage breast

R. Gelber, L. Mazzucchelli, B. Gusterson, 2006 .

Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V.

Per Karlsson, Zhuoxin Sun, J. Forbes, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer

J. Forbes, R. Gelber, A. Goldhirsch, 2004, British Journal of Cancer.

Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Updated safety analysis of trial BIG 1–98

A. Coates, B. Thürlimann, L. Mauriac, 2007 .

Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial.

G. Viale, K. Nielsen, B. Rasmussen, 2012 .

Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.

J. Forbes, R. Gelber, R. Paridaens, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bone Quality Test (BQT) scores of fingernails in postmenopausal patients treated with adjuvant letrozole or tamoxifen for early breast cancer.

R. Gelber, A. Goldhirsch, K. Price, 2009, Breast.

Comparing aromatase inhibitors in the absence of clinical trial results can be misleading

A. Goldhirsch, K. Price, 2007, Journal of surgical oncology.

Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose–response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer

A. Goldhirsch, A. Coates, B. Thürlimann, 1998 .

A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes.

M. Zelen, R. Gelber, A. Goldhirsch, 1985, Cancer research.

Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.

F. Cavalli, M. Bonetti, R. Gelber, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy

R. Gelber, A. Goldhirsch, G. Viale, 2010, Breast Cancer Research and Treatment.

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

J. Forbes, R. Gelber, R. Paridaens, 2005, The New England journal of medicine.

Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report.

J. Forbes, R. Gelber, A. Goldhirsch, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

P. Neven, R. Gelber, A. Goldhirsch, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.

A. Luini, R. Gelber, A. Goldhirsch, 2013, The Lancet. Oncology.

Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI.

M. Bonetti, R. Gelber, A. Goldhirsch, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience.

A. Goldhirsch, J. Collins, A. Coates, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00

R. Gelber, A. Goldhirsch, G. Pruneri, 2016, Breast Cancer Research and Treatment.

Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.

R. Gelber, B. Gusterson, A. Goldhirsch, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study.

A. Giobbie-Hurder, R. Gelber, T. Ahern, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.

A. Giobbie-Hurder, P. Neven, R. Gelber, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ki‐67 expression in breast carcinoma

R. Gelber, B. Gusterson, A. Goldhirsch, 2003, Cancer.

Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials.

R. Gelber, B. Gusterson, A. Goldhirsch, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.

A. Giobbie-Hurder, J. Forbes, R. Gelber, 2009, The New England journal of medicine.

Prognostic factors in childhood acute myelogenous leukemia.

R. Gelber, K. Price, M. Link, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).

R. Gelber, A. Goldhirsch, J. Collins, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.

R. Gelber, C. Geyer, N. Wolmark, 2014, The Lancet. Oncology.

Symptoms of endocrine treatment and outcome in the BIG 1-98 study

A. Giobbie-Hurder, J. Forbes, P. Neven, 2013, Breast Cancer Research and Treatment.

Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12–93

J. Forbes, R. Gelber, A. Goldhirsch, 2009, Breast Cancer Research and Treatment.

Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93.

R. Gelber, A. Goldhirsch, A. Coates, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.

R. Gelber, A. Goldhirsch, A. Coates, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.

R. Gelber, A. Goldhirsch, A. Coates, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor.

A. Goldhirsch, J. Collins, A. Coates, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93.

R. Gelber, A. Goldhirsch, D. Zahrieh, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.

M. Bonetti, R. Gelber, A. Goldhirsch, 2003, Journal of the National Cancer Institute.

Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: is chemotherapy necessary for premenopausal women with node-positive, endocrine-responsive breast cancer? First results of International Breast Cancer Study Group Trial 11–

J. Forbes, R. Gelber, A. Goldhirsch, 2001 .

Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer.

A. Giobbie-Hurder, R. Gelber, B. Gusterson, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group.

J. Torhorst, K. Price, R. Golouh, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study Group.

J. Forbes, F. Cavalli, R. Gelber, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.

R. Gelber, B. Gusterson, A. Goldhirsch, 2008, Journal of the National Cancer Institute.

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.

R. Gelber, B. Gusterson, A. Goldhirsch, 2008, The Lancet. Oncology.

Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.

P. Neven, R. Gelber, B. Gusterson, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer.

F. Monti, B. Gusterson, A. Goldhirsch, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials.

R. Gelber, A. Goldhirsch, J. Collins, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.

A. Giobbie-Hurder, B. Gusterson, A. Goldhirsch, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.

R. Gelber, B. Gusterson, A. Goldhirsch, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.

R. Gelber, H. Gómez, A. Goldhirsch, 2016, Journal of Clinical Oncology.

Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer : BIG 198

P. Neven, R. Gelber, B. Gusterson, 2007 .

Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial

B. Bonanni, R. Gelber, A. Goldhirsch, 2016, Breast Cancer Research.

Symptoms of endocrine treatment and outcome: A retrospective analysis of the monotherapy arms of the BIG 1-98 trial.

A. Giobbie-Hurder, J. Forbes, R. Paridaens, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.

R. Gelber, H. Gómez, A. Goldhirsch, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.

J. Forbes, R. Gelber, A. Goldhirsch, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients.

M. Zelen, R. Gelber, B. Gusterson, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial.

R. Gelber, C. Geyer, N. Wolmark, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Original article: Sequential estrogen receptor determinations from primary breast cancer and at relapse: Prognostic and therapeutic relevance

F. Cavalli, A. Goldhirsch, M. Castiglione, 1992 .

Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials

R. Gelber, A. Goldhirsch, G. MacGrogan, 2015, Breast Cancer Research and Treatment.

Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.

R. Gelber, A. Goldhirsch, J. Bernhard, 2015, The Lancet. Oncology.

Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.

R. Gelber, B. Gusterson, A. Goldhirsch, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Annexin A8 Is Up-Regulated During Mouse Mammary Gland Involution and Predicts Poor Survival in Breast Cancer

Joanna S Morris, B. Gusterson, G. Sauter, 2005, Clinical Cancer Research.

Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group.

R. Gelber, A. Goldhirsch, A. Coates, 2009, European journal of cancer.

Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence.

A. Giobbie-Hurder, J. Forbes, P. Neven, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.

István Láng, A. Giobbie-Hurder, J. Forbes, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience.

R. Gelber, A. Goldhirsch, J. Collins, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial.

R. Gelber, A. Goldhirsch, J. Bernhard, 2010, Breast.

The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer.

J. Forbes, R. Gelber, B. Gusterson, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of systemic adjuvant treatment on first sites of breast cancer relapse

G Marini, M. Tattersall, J. Forbes, 1994, The Lancet.

Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?

E. Perez, A. Goldhirsch, M. Regan, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Identifying B reast C ancer P atients a t H igh R isk f or Bone M etastases

F. Cavalli, M. Bonetti, R. Gelber, 2000 .

Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial

R. Gelber, A. Goldhirsch, J. Bernhard, 2011, Breast Cancer Research and Treatment.

Timing of radiotherapy and outcome in patients receiving adjuvant endocrine therapy.

A. Goldhirsch, K. Price, M. Castiglione‐Gertsch, 2011, International journal of radiation oncology, biology, physics.

Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93

J. Forbes, R. Gelber, A. Goldhirsch, 2008, Breast Cancer Research and Treatment.

Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast Cancer Study Group Trials VI and VII.

R. Gelber, A. Goldhirsch, M. Castiglione, 2016, International journal of radiation oncology, biology, physics.

The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up.

A. Goldhirsch, G. Viale, K. Price, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13-93 and 14-93

K. Price, S. Gelber, M. Colleoni, 2013, Breast Cancer Research and Treatment.

Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group

A. Goldhirsch, A. Coates, D. Crivellari, 2007, Supportive Care in Cancer.

Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.

R. Gelber, H. Gómez, A. Goldhirsch, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century

R. Gelber, A. Goldhirsch, J. Collins, 2009, Breast Cancer Research and Treatment.

Adjuvant ovarian function suppression and cognitive function in women with breast cancer

J. Forbes, R. Gelber, P. Maruff, 2016, British Journal of Cancer.

The best available adjuvant treatments are within the framework of clinical trials. The International Breast Cancer Study Group.

F. Cavalli, A. Goldhirsch, M. Castiglione, 1995, Israel journal of medical sciences.

Identifying breast cancer patients at high risk for bone metastases.

F. Cavalli, M. Bonetti, R. Gelber, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences

R. Gelber, A. Goldhirsch, A. Coates, 2014, Breast Cancer Research and Treatment.

Clinical trial update: International Breast Cancer Study Group

A. Goldhirsch, K. Price, 2005, Breast Cancer Research.

A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancer.

R. Gelber, A. Goldhirsch, G. Viale, 2012, Breast.

Timing breast cancer surgery

J. Forbes, R. Gelber, R. Blamey, 1991, The Lancet.

Prognostic value of Helix pomatia in breast cancer. International (Ludwig) Breast Cancer Study Group.

R. Gelber, M. Castiglione, H. Jayatilake, 1993, British Journal of Cancer.

Chemotherapy (CT) for isolated locoregional recurrence (ILRR) of breast cancer in ER-positive (ER+) and ER-negative (ER-) cohorts: Final analysis of the CALOR trial.

R. Gelber, N. Wolmark, J. Nortier, 2017 .

S3-1: Update of International Breast Cancer Study Group Trial 23-01 To Compare Axillary Dissection Versus No Axillary Dissection in Patients with Clinically Node Negative Breast Cancer and Micrometastases in the Sentinel Node.

A. Luini, R. Gelber, A. Goldhirsch, 2011 .

Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial.

R. Gelber, G. Viale, M. Regan, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

p 27 and Skp 2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer

F. Monti, B. Gusterson, A. Goldhirsch, 2009 .

Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer.

R. Gelber, B. Gusterson, A. Goldhirsch, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials.

R. Gelber, A. Goldhirsch, G. Viale, 2012 .

Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group.

M. Bonetti, R. Gelber, A. Goldhirsch, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial.

R. Gelber, R. Ruben, K. Price, 1988, The New England journal of medicine.

Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI.

F. Cavalli, R. Gelber, A. Goldhirsch, 1998, European journal of cancer.

Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience.

A. Goldhirsch, J. Collins, A. Coates, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.

A. Giobbie-Hurder, J. Forbes, R. Gelber, 2009, The New England journal of medicine.

Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX.

R. Gelber, A. Goldhirsch, F. Cardoso, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relative effectiveness of letrozole alone or in sequence with tamoxifen for patients diagnosed with invasive lobular carcinoma.

A. Giobbie-Hurder, E. Winer, J. Forbes, 2013 .

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).

R. Gelber, A. Goldhirsch, J. Collins, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Sequential estrogen receptor determinations from primary breast cancer and at relapse: prognostic and therapeutic relevance. The International Breast Cancer Study Group (formerly Ludwig Group).

F. Cavalli, R. Gelber, A. Goldhirsch, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Annexin A8 Is Up-Regulated During Mouse Mammary Gland Involution and Predicts Poor Survival in Breast Cancer

Joanna S Morris, B. Gusterson, G. Sauter, 2005, Clinical Cancer Research.

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

P. Neven, R. Gelber, A. Goldhirsch, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.

J. Forbes, R. Gelber, B. Gusterson, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Commentary Clinical trial update: International Breast Cancer Study Group

A. Goldhirsch, K. Price, 2005 .